Implementation of the HepC
Epidemiology
Health policy
Public health
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
To perform a budget impact analysis of the HepC We estimated the population of adult Pakistani migrants registered at the primary care centres in Catalonia by means of the Information System for the Development of Research in Primary Care (n=37 972 in 2019, Barcelona health area). This cohort was followed for a time period of 10 years after HCV diagnosis (2019-2028). The statistical significance of the differences observed in the anti-HCV positivity rate between screened and non-screened was confirmed (α=0.05). The budget impact was calculated from the perspective of the Catalan Department of Health. Sensitivity analyses included different levels of participation in HepC The HepC Scaling up the HepC
Identifiants
pubmed: 37604632
pii: bmjopen-2022-068460
doi: 10.1136/bmjopen-2022-068460
pmc: PMC10445371
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e068460Investigateurs
E Martró
(E)
V Saludes
(V)
A Antuori
(A)
A Not
(A)
S González-Gómez
(S)
J Gómez I Prat
(JG)
H Ouaarab
(H)
T Rafi
(T)
B Treviño
(B)
P Peremiquel-Trillas
(P)
S Tahir
(S)
N Serre
(N)
I Oliveira
(I)
J Casabona
(J)
J Reyes-Urueña
(J)
L Egea-Cortés
(L)
F Costell
(F)
L Ferrer
(L)
M Buti
(M)
M Riveiro-Barciela
(M)
L Roade
(L)
J Colom
(J)
X Major
(X)
E Buira
(E)
M Fàbregas
(M)
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: EM received lecture fees from Gilead Sciences and Abbvie, and research grants from Gilead Sciences. VS received travel sponsorship to attend scientific meetings from Gilead Sciences. MB received fees and research grants from Abbvie, Janssen and Gilead Sciences. The rest of authors have no conflict to declare.
Références
Int J Environ Res Public Health. 2020 Aug 21;17(17):
pubmed: 32825680
BMC Infect Dis. 2018 Jan 16;18(1):42
pubmed: 29338702
Public Health Rep. 2011 Jul-Aug;126(4):560-7
pubmed: 21800750
Liver Int. 2022 Aug;42(8):1751-1761
pubmed: 35635535
Enferm Infecc Microbiol Clin (Engl Ed). 2019 Apr;37(4):222-230
pubmed: 29759423
J Viral Hepat. 2021 Feb;28(2):288-299
pubmed: 33098176
Ann Intern Med. 2017 May 02;166(9):637-648
pubmed: 28319996
Euro Surveill. 2018 Mar;23(11):
pubmed: 29560855
PLoS One. 2015 Dec 21;10(12):e0145022
pubmed: 26689908
Value Health. 2022 Jan;25(1):10-31
pubmed: 35031088
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Mar;39(3):119-126
pubmed: 32451150
PLoS One. 2018 Nov 8;13(11):e0207037
pubmed: 30408079
Travel Med Infect Dis. 2021 Jan-Feb;39:101715
pubmed: 32389827
Rev Clin Esp. 2008 Oct;208(9):426-31
pubmed: 19000469
Lancet Gastroenterol Hepatol. 2019 Jan;4(1):32-44
pubmed: 30477810
Med Clin (Barc). 2012 May 19;138(14):617-21
pubmed: 22444996
Euro Surveill. 2019 Jul;24(30):
pubmed: 31362808
J Med Virol. 2018 Jan;90(1):131-141
pubmed: 28842995
Lancet Infect Dis. 2018 Sep;18(9):e259-e271
pubmed: 29778396
PLoS One. 2018 Nov 28;13(11):e0208036
pubmed: 30485377
BMJ. 2017 Jul 12;358:j3233
pubmed: 28701337
J Viral Hepat. 2018 Jun;25(6):670-679
pubmed: 29345847